Cosmo announces Cortiment® approval in Japan
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that its partner Ferring Pharmaceuticals (“Ferring”) has received the approval for Cortiment® (budesonide 9 mg MMX tablets) in Japan by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). First sales of Cortiment® in Japan are expected to begin by end of Q3 2023.